Who Generates Higher Gross Profit? AstraZeneca PLC or Amphastar Pharmaceuticals, Inc.

AstraZeneca vs. Amphastar: A Decade of Gross Profit Comparison

In the competitive landscape of pharmaceuticals, AstraZeneca PLC and Amphastar Pharmaceuticals, Inc. have showcased contrasting trajectories in gross profit over the past decade. From 2014 to 2023, AstraZeneca consistently outperformed Amphastar, with gross profits peaking at approximately $37.8 billion in 2023, a staggering 10,700% higher than Amphastar's $351 million in the same year.

AstraZeneca's dominance is evident, maintaining an average annual gross profit of around $23 billion, while Amphastar's average hovers near $151 million. Despite Amphastar's impressive growth, with a 585% increase from 2014 to 2023, AstraZeneca's robust financial performance underscores its leading position in the industry.

This analysis highlights the significant scale and market influence of AstraZeneca, offering insights into the financial dynamics of major pharmaceutical players over the years.